CooperCompanies has completed its strategic review, with the board unanimously deciding to retain CooperSurgical and expanding its share repurchase authorization from $2 billion to $3 billion. The company repurchased $445 million of shares this fiscal year and will prioritize investments in CooperVision while CooperSurgical focuses on organic growth and operational improvements. The board added two new independent directors and remains open to other value-creating alternatives. CooperCompanies also announced its Q3 2026 earnings results in a separate release.
The Cooper Companies, IncBoard completed strategic review, retained CooperSurgical, and expanded buyback authorization from $2B to $3B.
